NT_1170x120_1-11-18

Ralph Neas

GPhA tabs Davis as new CEO

GPhA tabs Davis as new CEO

WASHINGTON — Chester “Chip” Davis has been named president and chief executive officer of the Generic Pharmaceutical Association (GPhA), taking over from Ralph Neas, who is stepping down. GPhA said Wednesday that Davis, previously executive vice president for advocacy and member relations at Pharmaceutical Research and Manufacturers of America (PhRMA), is slated to start in

HHS to eye the pricing of generics

HHS to eye the pricing of generics

WASHINGTON — The federal government is looking into the effect of generic drug price increases on Medicaid. The Office of the Inspector General of the Department of Health and Human Services (HHS) will compare generic price increases between 2005 and 2014 to the inflation rate. The probe comes in response to questions raised about generics

Hamburg to step down as FDA commissioner

WASHINGTON — Dr. Margaret Hamburg, commissioner of the Food and Drug Administration, will step aside next month after nearly six years at the helm of the agency overseeing many of the nation’s most contentious public policy issues and products representing about 20% of every dollar spent by ­consumers. Hamburg, 59, said her decision to step

Neas to leave GPhA in the autumn

WASHINGTON — Ralph Neas, president and chief executive officer of the Generic Pharmaceutical Association, has announced he will step down from his position in the fall. Neas has led GPhA since September 2011. During his remaining tenure, he will continue to serve as CEO until a successor is named and will work to ensure a

Senate report calls for higher generics usage

WASHINGTON — Providing incentives to prescription drug plan sponsors that increase generic drug use is among recommendations that the Senate Special Committee on Aging unveiled last month in a bipartisan report that focuses on ways to increase the utilization of generics within the Medicare Part D program. The panel also heard about industry issues beyond

Sandoz biosimilar receives backing of FDA panel

WASHINGTON — A Food and Drug Administration panel has recommended that the agency approve what could become the country’s first biosimilar. The panel unanimously urged approval of Sandoz’s filgrastin (Neupogen), a cancer treatment. “This encouraging step forward means that it is very likely now only a question of when, rather than if, filgrastin will be available